FirstGeneration Anti-VEGF Therapies in Retinal Vascular Disease

In this opening segment, Dr. Harit Bhatt and Dr. Deepak Sambhara introduce the discussion on evolving standards of care in retinal vascular diseases, focusing on the pivotal role of aflibercept 2 mg. Dr. Bhatt highlights how this therapy has become the cornerstone of modern retinal treatment, shaping both clinical practice and the design of contemporary trials across wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO). Dr. Sambhara reflects on aflibercept’s enduring efficacy, safety, and durability, emphasizing its broad VEGF-binding mechanism—targeting VEGF-A, VEGF-B, and placental growth factor—which contributes to sustained anatomical and functional benefits. Both experts note that aflibercept’s safety record, built through extensive real-world experience, has solidified its role as the benchmark comparator in new anti-VEGF studies.